A new, observational study suggests that aspirin only marginally increases the bleeding risk in patients with diabetes mellitus, perhaps reflecting impaired platelet inhibition. Inconclusive evidence from small, randomized trials and mechanistic studies reinforces the need for larger trials to determine the relative cardioprotective benefits and bleeding risks of aspirin in these patients
Diabetes mellitus is an independent risk factor for cardiovascular disease (CVD). Accelerated develo...
Aspirin is effective for the prevention of cardiovascular events in patients with a history of vascu...
Introduction: Platelets of diabetic patients have been reported to be less sensitive to aspirin. The...
BACKGROUND: Patients with diabetes are at high cardiovascular (CV) risk due to an exaggerated platel...
Primary prevention of cardiovascular events with aspirin in patients with elevated cardiovascular ri...
Many clinical guidelines recommend aspirin therapy for the prevention of cardiovascular events in in...
Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevate...
BACKGROUND: The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CV...
The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular e...
The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular e...
Until recently, aspirin was recom-mended by most guidelines for theprimary prevention of cardiovascu...
Background: The systematic use of aspirin and statins in patients with diabetes and no previous card...
Background: Whether aspirin is of net clinical benefit for the primary prevention of vascular events...
PURPOSE: Aspirin is effective in secondary prevention of cardiovascular disease. The results are les...
Objectives To investigate the benefits and risks associated with aspirin treatment in patients with ...
Diabetes mellitus is an independent risk factor for cardiovascular disease (CVD). Accelerated develo...
Aspirin is effective for the prevention of cardiovascular events in patients with a history of vascu...
Introduction: Platelets of diabetic patients have been reported to be less sensitive to aspirin. The...
BACKGROUND: Patients with diabetes are at high cardiovascular (CV) risk due to an exaggerated platel...
Primary prevention of cardiovascular events with aspirin in patients with elevated cardiovascular ri...
Many clinical guidelines recommend aspirin therapy for the prevention of cardiovascular events in in...
Diabetes mellitus markedly increases the risk of cardiovascular diseases, with an especially elevate...
BACKGROUND: The clinical benefit of aspirin for the primary prevention of cardiovascular disease (CV...
The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular e...
The systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular e...
Until recently, aspirin was recom-mended by most guidelines for theprimary prevention of cardiovascu...
Background: The systematic use of aspirin and statins in patients with diabetes and no previous card...
Background: Whether aspirin is of net clinical benefit for the primary prevention of vascular events...
PURPOSE: Aspirin is effective in secondary prevention of cardiovascular disease. The results are les...
Objectives To investigate the benefits and risks associated with aspirin treatment in patients with ...
Diabetes mellitus is an independent risk factor for cardiovascular disease (CVD). Accelerated develo...
Aspirin is effective for the prevention of cardiovascular events in patients with a history of vascu...
Introduction: Platelets of diabetic patients have been reported to be less sensitive to aspirin. The...